Transient depressive relapse induced by catecholamine depletion: Potential phenotypic vulnerability marker?

Archives of General Psychiatry

Volumn 56, Issue 5, 1999, Pages 395-403

  Berman, Robert M ^a,b,c   Narasimhan, Meera ^b,c   Miller, Helen L ^b,c   Anand, Amit ^b,c   Cappiello, Angela ^b,c   Oren, Dan A ^b,c   Heninger, George R ^a,c   Charney, Dennis S ^a,b,c  

^a Yale University School of Medicine and the Connecticut Mental Health Center   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; CATECHOLAMINE; DIPHENHYDRAMINE; HOMOVANILLIC ACID; HYDROCORTISONE; METIROSINE; TYROSINE 3 MONOOXYGENASE;

ADULT; ARTICLE; CATECHOLAMINE DEPLETION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DROWSINESS; FEMALE; GAS CHROMATOGRAPHY; HAMILTON SCALE; HUMAN; MALE; MASS SPECTROMETRY; ORAL DRUG ADMINISTRATION; PHENOTYPE; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; RELAPSE;

ADULT; ALPHA-METHYLTYROSINE; CATECHOLAMINES; CROSS-OVER STUDIES; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; GENETIC MARKERS; HOMOVANILLIC ACID; HUMANS; MALE; METHOXYHYDROXYPHENYLGLYCOL; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; SEVERITY OF ILLNESS INDEX;

EID: 0032931856     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.56.5.395     Document Type: Article

References (57)

1. Bunney WE Jr, Davis JM. Norepinephrine in depressive reactions: a review. Arch Gen Psychiatry. 1965;13:483-494.
2. Kapur S, Mann J. Role of the dopaminergic system in depression. Biol Psychiatry. 1992;32:1-17.
3. Randrup A, Munkvad I, Fog R, Molauder L, Kjellberg B. Mania, depression, and brain dopamine. In: Essman W, Valzelli L, eds. Current Developments in Psychopharmacology. New York, NY: Spectrum Publications; 1975:207-229.
4. Schildkraut J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965;122:509-521.
5. Willner P. Dopaminergic mechanisms in depression and mania. In: Bloom F, Kupfer D, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:921-932.
6. Siever L, Davis K. Overview: toward a dysregulation hypothesis of depression. Am J Psychiatry. 1985;142:1017-1032.
7. Mendels J, Frazer A. Brain biogenic amine depletion and mood. Arch Gen Psychiatry. 1974;30:447-451.
8. Engelman K, Horwitz D, Jequier E, Sjoerdsma A. Biochemical and pharmacologie effects of α-methyltyrosine in man. J Clin Invest. 1968;47:577-594.
9. Sjoerdsma A, Engelman K, Spector S, Udenfriend S. Inhibition of catecholamine synthesis in man with α-methyl-tyrosine, an inhibitor of tyrosine hydroxylase. Lancet. 1965;2:1092-1094.
10. Colwill J, Dutton A, Morissey J, Yu P. Alphamethyldopa and hydrochlorothiazide: a controlled study of the comparative effectiveness of antihypertensive agents. N Engl J Med. 1964;271:696-703.
11. Dollerey C, Harington M. Methyldopa in depression: clinical and pharmacological studies. Lancet. 1962;1:759-763.
12. Horwitz D, Sjoerdsma H. Use of two enzyme inhibitors in hypertension therapy. Postgrad Med. 1963;34:140-144.
13. Smirk F, McQueen E. Comparison of rescinnamine and reserpine as hypertensive agents. Lancet. 1955;9:115-116.
14. Goodwin F, Bunney W. Depressions following reserpine: a reevaluation. Semin Psychiatry. 1971;3:435-448.
15. Delgado PL, Miller HL, Salomon RM, Licinio J, Heninger GR, Gelenberg AJ, Charney DS. Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol Bull. 1993;29:389-396.
16. Miller HL, Delgado PL, Salomon RM, Berman R, Krystal JH, Heninger GR, Charney DS. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiatry. 1996; 53:117-128.
17. Miller H, Delgado P, Salomon R, Heninger G, Charney D. Effects of α-methyl-para-tyrosine (AMPT) in drug-free depressed patients. Neuropsychopharmacology. 1996;14:151-157.
18. Salomon R, Miller H, Krystal J, Heninger G, Charney D. Lack of behavioral effects of monoamine depletion in healthy subjects. Biol Psychiatry. 1997;41: 58-64.
19. Brodie H, Murphy D, Goodwin F, Bunney W. Catecholamines and mania: the effect of α-methyl-para-tyrosine on manic behavior and catecholamine metabolism. Clin Pharmacol Ther. 1971;12:218-224.
20. McCann UD, Penetar DM, Shaham Y, Thorne DR, Gillin JC, Sing HC, Thomas MA, Belenky G. Sleep deprivation and Impaired cognition: possible role of brain catecholamines. Biol Psychiatry. 1992;31:1082-1097.
21. Zimmermann RC, Krahn L, Klee G, Delgado P, Dry SJ, Lin SC. Inhibition of presynaptic catecholamine synthesis with α-methyl-para-tyrosine attenuates nocturnal melatonin secretion in humans. J Clin Endocrinol Metab. 1994;79: 1110-1114.
22. McCann UD, Ricaurte GA. Strategies for detecting subclinical monoamine depletions in humans. NIDA Res Monogr. 1993;136:53-62.
23. McCann UD, Thorne D, Hall M, Popp K, Avery W, Sing H, Thomas M, Belenky G. The effects of L-dihydroxyphenylalanine on alertness and mood in α-methyl-para-tyrosine-treated healthy humans: further evidence for the role of catecholamines in arousal and anxiety. Neuropsychopharmacology. 1995;13:41-52.
24. Ribeiro S, Tandon R, Grunhaus L, Greden J. The DST as a predictor of outcome in depression: a meta-analysis. Am J Psychiatry. 1993;150:1618-1629.
25. Mazure C, Nelson CJ, Price LH. Reliability and validity of the symptoms of major depressive illness. Arch Gen Psychiatry. 1986;43:451-456.
26. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987.
27. Sweet RD, Bruun R, Shapiro E, Shapiro AK. Presynaptic catecholamine antagonists as treatment for Tourette syndrome: effects of α methyl para tyrosine and tetrabenazine. Arch Gen Psychiatry. 1974;31:857-861.
28. Woods SW, Charney DS, Goodman WK, Heninger GR. Carbon dioxide-induced anxiety: behavioral, physiologic, and biochemical effects of carbon dioxide in patients with panic disorders and healthy subjects. Arch Gen Psychiatry. 1988; 45:43-52.
29. Maas J, Hattox S, Landis O. The determination of a brain arteriovenous difference for 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG). Brain Res. 1976; 118:167-173.
30. Bacopoulos N, Redmond D, Roth R. Serotonin and dopamine metabolites in brain regions and cerebrospinal fluid of a primate species: effects of ketamine and fluphenazine. J Neurochem. 1979;32:1215-1218.
31. Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GK. Serotonin function and the mechanism of antidepressant action: reversal of antidepressant-induced remission by rapid depletion of plasm tryptophan. Arch Gen Psychiatry. 1990;47:411-418.
32. McCann UD, Penetar DM, Shaham Y, Thorne DR, Sing HC, Thomas ML, Gillin JC, Belenky G. Effects of catecholamine depletion on alertness and mood in rested and sleep-deprived normal volunteers. Neuropsychopharmacology. 1993;8:345-356.
33. McCann JD, Penetar DM, Belenky G. Panic attacks in healthy volunteers treated with a catecholamine synthesis inhibitor. Biol Psychiatry. 1991;30:413-416.
34. McCann JD, Penetar DM, Belenky G. Acute dystonic reaction in normal humans caused by catecholamine depletion. Clin Neuropharmacol. 1990;13:565-568.
35. Bunney WE, Brodie HK, Murphy DL, Goodwin FK. Studies of α-methyl-para-tyrosine, L-dopa, and L-tryptophan in depression and mania. Am J Psychiatry. 1971;127:872-881.
36. Klimek V, Stockmeier C, Overholser J, Melker H, Kalka S, Dilley G, Ordway G. Reduced levels of norepinephrine transporters In the locus coeruleus in major depression. J Neurosci. 1997;17:8451-8458.
37. Ordway G, Smith I, Haycock J. Elevated tyrosine hydroxylase in the locus coeruleus of suicide victims. J Neurochem. 1994;62:680-685.
38. Nestler EJ, McMahon A, Sabban EL, Tallman JF, Duman RS. Chronic antidepressant administration decreases the expression of tyrosine hydroxylase in the rat locus coeruleus. Proc Natl Acad Sci U S A. 1990;87:7522-7526.
39. Blanchard V, Raisman-Vozare R, Savasta M, Hirsch E, Javoy-Agid F, Feuerstein C, Agid Y. Cellular quantification of tyrosine hydroxylase in the rat brain by immunoautoradiography. J Neurochem. 1993;61:617-626.
40. Melia KR, Rasmussen K, Terwiliger RZ, Haycock JW, Nestler EJ, Duman RS. Coordinate regulation of the cyclic AMP system with firing rate and expression of tyrosine hydroxylase in the rat locus coeruleus: effects of chronic stress and drug treatments. J Neurochem. 1992;58:494-502.
41. Smialowska M. An inhibitory dopaminergic regulation of the neuropeptide Y immunoreactivity expression in the rat cerebral cortex neurons. Neuroscience. 1995; 66:589-595.
42. Suda T, Tomorl N, Yajima F, Sumitomo T, Nakagami Y, Ushiyama T, Demura H, Shizume K. Time course study on the effect of reserpine on hypothalamic immunoreactive CRF levels In rats. Brain Res. 1987;405:247-252.
43. Molinengo L, Ghi P, Oggero L, Orsetti M. Behavioral and neurochemical modifications caused by chronic α-methylparatyrosine administration. Pharmacol Biochem Behav. 1992;39:437-442.
44. Hale AS, Sandier M, Hannah P, Glover V, Bridges PK. Tyramine conjugation test distinguishes unipolar from bipolar depressed patients and controls. J Psychiatr Res. 1991;25:185-190.
45. Harrison WM, Cooper TB, Stewart JW, Ouitkin FM, McGrath PJ, Liebowitz MR, Rabkin JR, Markcwitz JS, Klein DF. The tyramine challenge test as a marker for melancholia. Arch Gen Psychiatry. 1984;41:681-685.
46. Bonham Carter S, Reveley M, Sandler M, Dewhurst J, Little B, Hayworth J, Priest R. Decreased urinary output of conjugated tyramine is associated with lifetime vulnerability to depressive illness. Psychiatry Res. 1980;3:13-21.
47. Siever L, Uhde T, Silberman E, Jimerson D, Aloi J, Post R, Murphy D. Growth hormone response to clonidine as a probe of noradrenergic receptors responsiveness in affective disorder patients and controls. Psychiatry Res. 1982;6: 171-183.
48. Shittecate M, Charles G, Machowski R, Garcia-Valenfin J, Wilmotte J. Controversies about the clonidine test. In: Ansseau M, von Frenckell R, Franck G, eds. Biological Markers of Depression. Amsterdam, the Netherlands: Elsevier Science Publishers; 1991:59-62.
49. Schatzberg A, Schildkraut J. Recent studies on norepinephrine systems in mood disorders. In: Bloom F, Kupfer D, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:911-920.
50. Banki CM, Kamnacsi L, Bissette G, Nemeroff CB. CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse. Eur Neuropsychopharmacol. 1992;2:107-113.
51. Redmond D, Maas J, Kling A, Graham C, Dekirmenjlian H. Social behavior of monkeys selectively depleted of monoamines. Science. 1971;174:428-431.
52. Suomi S. Social development in rhesus monkeys: consideration of individual differences. In: Oliverio A, Zappella M, eds. The Behavior of Human Infants. New York, NY: Plenum Publishing Corp; 1983:161-182.
53. Kraemer GW, McKinney WT. Interactions of pharmacological agents which alter biogenic amine metabolism and depression: an analysis of contributing factors within a primate model of depression. J Affect Disord. 1979;1:33-54.
54. Smith EL, Coplan JD, Trost RC, Scharf BA, Rosenblum LA. Neurobiological alterations in adult nonhuman primates exposed to unpredictable early rearing: relevance to posttraumatic stress disorder. Ann N Y Acad Sci. 1997;821: 545-548.
55. Coplan JD, Andrews MW, Rosenblum LA, Owens MJ, Friedman S, Gorman JM, Nemeroff CB. Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult nonhuman primates exposed to early-life stressors: implications for the pathophysiology of mood and anxiety disorders. Proc Natl Acad Sci U S A. 1996;93:1619-1623.
56. Coplan J, Smith E, Trost R, Scharff B, Bjornsen L, Owens M, Nemeroff C, Gorman J, Rosenbaum L. Growth hormone response to clonidine in adversely-reared primates and inhibitory role of corticotropin-releasing factor. In: Program and abstracts of the 36th Annual Meeting of the American College of Neuropsychopharmacology; December 8-12, 1997; Waikoloa, Hawaii. 1997:129.
57. Coplan JD, Pine DS, Papp LA, Gorman JM. A view on noradrenergic, hypothalamic-pituitary-adrenal axis and extrahypothalamic corticotrophin-releasing factor function in anxiety and affective disorders: the reduced growth hormone response to clonidine. Psychopharmacol Bull. 1997;33:193-204.